Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (10046)	1/16/2004 10:16:56 AM
From: Icebrg	Read Replies (1) \| Respond to of 52153

>>Looks like ceph is on track with the isomer version and if filing and approval are timely they should beat generics to the market. If so, I think the upside to the program may surprise.>> Yes, I saw that. I wonder however how much of a real benefit a longer-acting version of Modafinil will bring. I believe Cephalon's main line of defense might still be the particle size patent. If the only advantage the isomeric version will give is slightly more convenience I believe many will prefer a less expensive version, if one would appear. I held Cephalon for some time, but sold when I realised that there was also a generic threat hanging over Actiq. That was one drug too much. And I wasn't too impressed by the CIMA purchase either. Cephalon has a lot of debt now. Erik